1
|
Hutton C, Heider F, Blanco-Gomez A, Banyard A, Kononov A, Zhang X, Karim S, Paulus-Hock V, Watt D, Steele N, Kemp S, Hogg EKJ, Kelly J, Jackstadt RF, Lopes F, Menotti M, Chisholm L, Lamarca A, Valle J, Sansom OJ, Springer C, Malliri A, Marais R, Pasca di Magliano M, Zelenay S, Morton JP, Jørgensen C. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell 2021; 39:1227-1244.e20. [PMID: 34297917 PMCID: PMC8443274 DOI: 10.1016/j.ccell.2021.06.017] [Citation(s) in RCA: 169] [Impact Index Per Article: 56.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Revised: 04/19/2021] [Accepted: 06/25/2021] [Indexed: 12/18/2022]
Abstract
Fibroblasts display extensive transcriptional heterogeneity, yet functional annotation and characterization of their heterocellular relationships remains incomplete. Using mass cytometry, we chart the stromal composition of 18 murine tissues and 5 spontaneous tumor models, with an emphasis on mesenchymal phenotypes. This analysis reveals extensive stromal heterogeneity across tissues and tumors, and identifies coordinated relationships between mesenchymal and immune cell subsets in pancreatic ductal adenocarcinoma. Expression of CD105 demarks two stable and functionally distinct pancreatic fibroblast lineages, which are also identified in murine and human healthy tissues and tumors. Whereas CD105-positive pancreatic fibroblasts are permissive for tumor growth in vivo, CD105-negative fibroblasts are highly tumor suppressive. This restrictive effect is entirely dependent on functional adaptive immunity. Collectively, these results reveal two functionally distinct pancreatic fibroblast lineages and highlight the importance of mesenchymal and immune cell interactions in restricting tumor growth.
Collapse
Affiliation(s)
- Colin Hutton
- Systems Oncology, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Felix Heider
- Systems Oncology, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Adrian Blanco-Gomez
- Systems Oncology, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Antonia Banyard
- Flow Cytometry Core, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Alexander Kononov
- Systems Oncology, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Xiaohong Zhang
- Systems Oncology, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Saadia Karim
- Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK
| | - Viola Paulus-Hock
- Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK
| | - Dale Watt
- Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK
| | - Nina Steele
- University of Michigan, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA; Department of Cell and Developmental Biology, Ann Arbor, MI 48109, USA
| | - Samantha Kemp
- Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA; Molecular and Cellular Pathology Graduate Program, University of Michigan, Ann Arbor, MI 48109, USA
| | - Elizabeth K J Hogg
- Systems Oncology, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Joanna Kelly
- Systems Oncology, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Rene-Filip Jackstadt
- Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK
| | - Filipa Lopes
- Drug Discovery Unit, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Matteo Menotti
- Cell Signalling, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Luke Chisholm
- Molecular Oncology, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Angela Lamarca
- Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
| | - Juan Valle
- Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK; Institute of Cancer Sciences, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK
| | - Owen J Sansom
- Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Switchback Road, Garscube Estate, Glasgow G61 1QH, UK
| | - Caroline Springer
- Drug Discovery Unit, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Angeliki Malliri
- Cell Signalling, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Richard Marais
- Molecular Oncology, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Marina Pasca di Magliano
- University of Michigan, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA
| | - Santiago Zelenay
- Cancer Immunity and Inflammation, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK
| | - Jennifer P Morton
- Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Switchback Road, Garscube Estate, Glasgow G61 1QH, UK
| | - Claus Jørgensen
- Systems Oncology, Cancer Research UK Manchester Institute, Alderley Park, Manchester SK10 4TG, UK.
| |
Collapse
|